AU2021106785C4 - Combined plant compounds for use in the treatment of viral infections including covid-19 - Google Patents
Combined plant compounds for use in the treatment of viral infections including covid-19 Download PDFInfo
- Publication number
- AU2021106785C4 AU2021106785C4 AU2021106785A AU2021106785A AU2021106785C4 AU 2021106785 C4 AU2021106785 C4 AU 2021106785C4 AU 2021106785 A AU2021106785 A AU 2021106785A AU 2021106785 A AU2021106785 A AU 2021106785A AU 2021106785 C4 AU2021106785 C4 AU 2021106785C4
- Authority
- AU
- Australia
- Prior art keywords
- approximately
- zingiber officinale
- glycine max
- siraitia grosvenorii
- angelica dahurica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 48
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 31
- 208000036142 Viral infection Diseases 0.000 title abstract description 10
- 230000009385 viral infection Effects 0.000 title abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 130
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 122
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 122
- 235000008397 ginger Nutrition 0.000 claims abstract description 122
- 239000001841 zingiber officinale Substances 0.000 claims abstract description 122
- 244000291564 Allium cepa Species 0.000 claims abstract description 77
- 235000005255 Allium cepa Nutrition 0.000 claims abstract description 77
- 235000011446 Amygdalus persica Nutrition 0.000 claims abstract description 77
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 77
- 241001549572 Elsholtzia splendens Species 0.000 claims abstract description 77
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 77
- 244000068988 Glycine max Species 0.000 claims abstract description 77
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims abstract description 77
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims abstract description 77
- 240000007171 Imperata cylindrica Species 0.000 claims abstract description 77
- 244000273256 Phragmites communis Species 0.000 claims abstract description 77
- 235000014676 Phragmites communis Nutrition 0.000 claims abstract description 77
- 240000005809 Prunus persica Species 0.000 claims abstract description 77
- 244000185386 Thladiantha grosvenorii Species 0.000 claims abstract description 77
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims abstract description 77
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 76
- 235000006751 Platycodon Nutrition 0.000 claims abstract description 75
- 229930189914 platycodon Natural products 0.000 claims abstract description 75
- 235000017617 Lonicera japonica Nutrition 0.000 claims abstract description 65
- 244000167230 Lonicera japonica Species 0.000 claims abstract description 65
- 235000007007 Dolichos lablab Nutrition 0.000 claims abstract description 49
- 244000046095 Psophocarpus tetragonolobus Species 0.000 claims abstract description 49
- 235000007354 Coix lacryma jobi Nutrition 0.000 claims abstract description 48
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 48
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 48
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 40
- 235000006533 astragalus Nutrition 0.000 claims abstract description 40
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 38
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 38
- 235000021511 Cinnamomum cassia Nutrition 0.000 claims abstract description 38
- 241000572565 Alpinia oxyphylla Species 0.000 claims abstract description 34
- 235000010686 Agastache rugosa Nutrition 0.000 claims abstract description 33
- 240000004510 Agastache rugosa Species 0.000 claims abstract description 33
- 244000141331 Amomum villosum Species 0.000 claims abstract description 32
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 32
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 32
- 240000005250 Chrysanthemum indicum Species 0.000 claims abstract description 23
- 235000018959 Chrysanthemum indicum Nutrition 0.000 claims abstract description 23
- 241000292546 Taraxacum mongolicum Species 0.000 claims abstract description 23
- 244000241463 Cullen corylifolium Species 0.000 claims abstract description 22
- 241000576429 Forsythia suspensa Species 0.000 claims abstract description 22
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 22
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 22
- 241001078983 Tetradium ruticarpum Species 0.000 claims abstract description 22
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 18
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 18
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 16
- 240000001972 Gardenia jasminoides Species 0.000 claims abstract description 16
- 244000137773 Viola philippica Species 0.000 claims abstract description 16
- 241000425308 Begonia fimbristipula Species 0.000 claims abstract description 14
- 235000009421 Myristica fragrans Nutrition 0.000 claims abstract description 14
- 244000270834 Myristica fragrans Species 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 13
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims abstract description 10
- 240000006927 Foeniculum vulgare Species 0.000 claims abstract description 10
- 244000089698 Zanthoxylum simulans Species 0.000 claims abstract description 10
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 9
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 9
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 9
- 241001571446 Scaphium scaphigerum Species 0.000 claims abstract description 9
- 244000268590 Euryale ferox Species 0.000 claims abstract description 8
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 8
- 235000005911 diet Nutrition 0.000 claims description 39
- 230000000378 dietary effect Effects 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 238000013329 compounding Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 33
- 208000016255 tiredness Diseases 0.000 description 16
- 230000003867 tiredness Effects 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- 229920002774 Maltodextrin Polymers 0.000 description 14
- 239000005913 Maltodextrin Substances 0.000 description 14
- 229940035034 maltodextrin Drugs 0.000 description 14
- 210000000582 semen Anatomy 0.000 description 14
- 241000245240 Lonicera Species 0.000 description 12
- 206010011224 Cough Diseases 0.000 description 8
- 241000628997 Flos Species 0.000 description 8
- 208000000112 Myalgia Diseases 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 208000013465 muscle pain Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000234282 Allium Species 0.000 description 6
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 6
- 206010068319 Oropharyngeal pain Diseases 0.000 description 6
- 201000007100 Pharyngitis Diseases 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 235000021251 pulses Nutrition 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 230000008817 pulmonary damage Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 206010057244 Post viral fatigue syndrome Diseases 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000767840 Semiaquilegia Species 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 208000030247 mild fever Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 241001529821 Agastache Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010065369 Burnout syndrome Diseases 0.000 description 1
- 241000209205 Coix Species 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012674 herbal formulation Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
The present invention is directed to a compound herbal composition for treatment of or prevention of
COVID-19 or other viral infections, and/or treatment of or prevention of one or more of medical conditions
resulting from COVID-19, comprising: Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine
max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites
australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica. Further extracts can also be added to this
base composition, including Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis,
Scutellaria baicalensis, Forsythia suspensa, Dolichos lablab, Coix lachryma-jobi, Agastache rugosa, Myristica
fragrans, Cinnamomum cassia, Zingiber officinale, Foeniculum vulgare, Zanthoxylum bungeanum,
Astragalus membranaceus, Chrysanthemum indicum, Taraxacum mongolicum, Viola yedoensis, Begonia
fimbristipula, Scaphium scaphigerum, Houttuynia cordata, Gardenia jasminoides, Nelumbo nucifera,
Lophatherum gracile, Houttuynia cordata, Dioscorea oppositifolia, Amomum villosum, Cornus officinalis
and Euryale ferox.
Description
COMBINED PLANT COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19
Field of the Invention
[1] The present invention relates to compound herbal composition and in particular to combined plant compounds for use in treatment of viral infections.
[2] The invention has been developed primarily for use in treating COVID-19 and related complications and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
Background of the Invention
[3] TheCOVID-19 pandemicin theworld has infected millionsof people and caused many deaths.
[4] At an early stage of the COVIC19 pandemic, China's hospital system was overwhelmed with COVID patients and death rate was very high.
[5] Chinese herbal medication (CHM) which comprises combined plant compounds has been used to treat symptoms of COVID-19. In a recent study, Fan et al in a review article titled "Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis", reported on various controlled trials in China where CHM has been used to treat COVID-19. Itwasfound thattreatment including CHM reduced symptoms in a number of patients with COVID-19.
[6] On 20 August 2021, there have been 209,876,613 confirmed global cases of Covid 19, 122,586 cases in China. There have been 4,400,284 deaths. 5674 cased in China, reported to WHO. Six months after reaching 100 million cases effected by new variants it has been reported that there are 21,446 cases in China. The rate of mortality and growth in number of cases in China is significantly lower than the global rate. Treatment by CHM has likely played an important role, because CHM is not only used in the treatment of confirmed patients, but is also widely used in the prevention of COVID-19 for public in China.
[7] Due to differences in geographic and environmental conditions, dietary traditions, and demographic variations, the CHM medications vary in efficaciousness.
[8] The present invention seeks to provide a compound herbal composition which will overcome or substantially ameliorate at least some of the deficiencies of the prior art, or to at least provide an alternative.
[9] It is to be understood that, if any prior art information is referred to herein, such reference does not constitute an admission that the information forms part of the common general knowledge in the art, in Australia or any other country.
Summary of the Invention
[10] In accordance with an aspect of the present disclosure, there is provided a compound herbal composition for treatment of or prevention of COVID-19 or other viral infections, and/or treatment of or prevention of one or more of medical conditions resulting from COVID-19, comprising: Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras , Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica, wherein the composition is prepared by compounding a therapeutically effective combination of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica.
[11] Use of the compound herbal composition in a therapeutically effective amount in the manufacture of a medicament for administration to a patient in the therapeutic treatment of and/or prevention of COVID-19 or other viral infections and/or treatment of and/or prevention of one or more of medical conditions resulting from COVID-19, is provided.
[12] The composition may further comprise Tetradium ruticarpum.
[13] The composition may further comprise Alpinia oxyphylla.
[14] The composition may further comprise Cullen corylifolium.
[15] The composition may further comprise Cornus officinalis.
[16] The composition may further comprise Scutellaria baicalensis.
[17] The composition of may further comprise Forsythia suspensa.
[18] The composition of may further comprise Dolichos lablab.
[19] The composition may further comprise Coix lachryma-jobi.
:3
[20] The composition may further comprise an effective amount of each of Agastache rugosa.
[21] The composition may further comprise Myristica fragrans.
[22] The composition may further comprise Cinnamomum cassia.
[23] The composition may further comprise Zingiber officinale.
[24] The composition may further comprise Foeniculum vulgare.
[25] The composition may further comprise Zanthoxylum bungeanum.
[26] The composition may further comprise Astragalus membranaceus.
[27] The composition may further comprise Chrysanthemum indicum.
[28] The composition may further comprise Taraxacum mongolicum.
[29] The composition may further comprise Viola yedoensis.
[30] The composition may further comprise Begonia fimbristipula.
[31] The composition may further comprise Scutellaria baicalensis.
[32] The composition may further comprise Forsythia suspensa.
[33] The composition may further comprise Scaphium scaphigerum.
[34] The composition may further comprise Houttuynia cordata.
[35] The composition may further comprise Gardenia jasminoides.
[36] The composition may further comprise Nelumbo nucifera.
[37] The composition may further comprise Lophatherum gracile.
[38] The composition may further comprise Houttuynia cordata.
[39] The composition may further comprise Dioscorea oppositifolia.
[40] The composition may further comprise Amomum villosum.
[41] The composition may further comprise Cornus officinalis.
[42] The composition may further comprise Euryale ferox.
[43] An effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica in the therapeutically effective combination may comprise between 6.5 wt% to lOwt% of Angelica dahurica, between 3 to 4.5 wt% of Elsholtzia splendens, between 5.5 wt% to 8 wt% of Lonicera japonica, between 8.5 wt% to 12.5wt% of Glycine max, between 7 wt% to 10.5wt% of Siraitia grosvenorii, between 7 wt% to 10.5 wt% of Zingiber officinale, between 8.5 wt% to 12.5% of Platycodon grandifloras, between 7.5 wt% to 10.5 wt % of Imperata cylindrica, between 3.0 wt% to 5.0 wt% of Phragmites australis, between 3.0 wt% to 4.5 wt% of Allium cepa, between 7 wt% to 10.5 wt% of Glycyrrhiza uralensis and between 3 wt% to 4.5 wt% of Prunus persica.
[44] The composition may comprise an additive. The additive may be maltodextrin.
[45] The compound herbal composition may be provided in any one of the following dosage forms: powdered form or tablet or capsule or paste or liquid form for oral consumption, or inhalants or injectable liquid. The liquid form for oral consumption may be a concentrated or a diluted drink.
[46] In another aspect, there is provided a method of treating COVID-19 or other viral infections, and/oroneormore medical conditions resultingfrom COVID-19 in asubject in need thereof, comprising administering a therapeutically effective amount of the compound herbal composition.
[47] The one or more medical conditions may comprise pneumonia and/or acute respiratory syndrome and/or persistent pulmonary damage and/or post-viral fatigue and/or chronic cardiac complications.
[48] A method of preventing occurrence and/or reducing severity of one or more medical conditions resulting from COVID-19 and/or improving human body immunity in a subject in need thereof, comprises administering a therapeutically effective amount of the compound herbal composition.
[49] The one or more medical conditions may comprise pneumonia and/or acute respiratory syndrome and/or persistent pulmonary damage and/or post-viral fatigue and/or chronic cardiac complications.
[50] An effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica in the therapeutically effective combination for a medicinal version for a cold body constitution may comprise approximately 9 wt% of Angelica dahurica, approximately 4 wt% of Elsholtzia splendens, approximately 7.8 wt% of Lonicera japonica, approximately 12.5wt% of Glycine max, approximately 10 wt% Siraitia grosvenorii, approximately 10 wt% of Zingiber officinale, 10 % of Platycodon grandifloras, approximately 12 wt % of Imperata cylindrica, 5.0 wt% of Phragmites australis, 4.2 wt% of Allium cepa, approximately 10.3 wt% of Glycyrrhiza uralensis and 4.2 wt% of Prunus persica.
[51] The composition may further comprise Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Scutellaria baicalensis, and Forsythia suspensa, wherein an effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica, Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Scutellaria baicalensis, and Forsythia suspensa in the therapeutically effective combination for a medicinal version for a subject having a cold body constitution and may comprise approximately 6.5 wt% of Angelica dahurica, approximately 3 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 10 wt% of Platycodon grandifloras, approximately 12 wt % of Imperata cylindrica, approximately 5.0 wt% of Phragmites australis, approximately 4.2 wt% of Allium cepa, approximately 10.3 wt % of Glycyrrhiza uralensis, approximately 4.2 wt% of Prunus persica, approximately 5.9 wt% Tetradium ruticarpum, approximately 4.8 wt% Alpinia oxyphylla, approximately 5.4 wt% Cullen corylifolium, approximately 5.2 wt% Cornus officinalis, approximately 3.6 wt% Scutellaria baicalensis, and approximately 3.5 wt% Forsythia suspensa.
[52] The composition may further comprise Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Dolichos lablab, and Coix lachryma-jobi,wherein an effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica,
Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Dolichos lablab, and Coix lachryma-jobi in the therapeutically effective combination for a dampness resolving medicinal version for a subject having a cold body constitution that may comprise approximately 6.5 wt% of Angelica dahurica, approximately 3 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 8.7 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 % of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 5.7 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 5.7 wt% of Tetradium ruticarpum, approximately 4.8 wt% of Alpinia oxyphylla, approximately 5.2 wt% of Cullen corylifolium, approximately 5.2 wt% of Cornus officinalis, approximately 2.6 wt% of Dolichos lablab, and approximately 4.8 wt% Coix lachryma-jobi.
[53] The composition may further comprise Agastache rugosa, Myristica fragrans, Cinnamomum cassia, Zingiber officinale (Dry), and Alpinia oxyphylla, wherein an effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica, Agastache rugosa, Myristica fragrans, Cinnamomum cassia, Zingiber officinale(Dry), Alpinia oxyphylla in the therapeutically effective combination for a dietary version for a subject having a cold body constitution and may comprise approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 % of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately approximately 5.7 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 1.1 wt% of Agastache rugosa, approximately 7.3 wt% of Myristica fragrans, approximately 1.5 wt% of Cinnamomum cassia, approximately 11.1 wt% of Zingiber officinale(Dry) and approximately 7.3 wt% of Alpinia oxyphylla.
[54] The composition may further comprise Agastache rugosa, Myristica fragrans, Cinnamomum cassia, Zingiber officinale (Dry), and Alpinia oxyphylla, wherein an effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras , Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica,
Foeniculum vulgare, Zanthoxylum bungeanum, Zingiber officinale(Dry), Astragalus membranaceus, Agastache rugosa, Dolichos lablab, and Coix lachryma-jobi in the therapeutically effective combination for dampness resolving dietary version for a subject having a cold body constitution and may comprise approximately 6.8 wt% of Angelica dahurica, approximately 3.2 wt% of Elsholtzia splendens, approximately 5.9 wt% of Lonicera japonica, approximately 9.1 wt% of Glycine max, approximately 7.8 wt% Siraitia grosvenorii, approximately 7.8 wt% of Zingiber officinale, approximately 9.1 % of Platycodon grandifloras, approximately 7.8 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.2 wt% of Allium cepa, approximately 7.8 wt% of Glycyrrhiza uralensis, approximately 3.2 wt% of Prunus persica, approximately 4.6 wt% of Foeniculum vulgare, approximately 4.6 wt% of Zanthoxylum bungeanum, approximately 4.6 wt % of Zingiber officinale(Dry), approximately 6.8 wt% of Astragalus membranaceus, approximately 1.4 wt% of Agastache rugosa, approximately 2.8 wt% of Dolichos lablab, and approximately 5.0 wt% of Coix lachryma-jobi.
[55] The composition may further comprise Chrysanthemum indicum, Taraxacum mongolicum, Viola yedoensis, Begonia fimbristipula, Scutellaria baicalensis, Forsythia suspensa in the therapeutically effective combination for a medicinal version for a subject having a hot body constitution and may comprise approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 % wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 6.3 wt %of Chrysanthemum indicum, approximately 4.7 wt% of Taraxacum mongolicum, approximately 4.2 wt% of Viola yedoensis, approximately 4.3 wt% of Begonia fimbristipula, approximately 4.3 wt% Scutellaria baicalensis, and approximately 4.3 wt% of Forsythia suspensa.
[56] The composition of claim 1, may further comprise Chrysanthemum indicum, Taraxacum mongolicum, Viola yedoensis, Begonia fimbristipula, Scutellaria baicalensis, Forsythia suspensa in the therapeutically effective combination for a dampness resolving medicinal version for a subject having a hot body constitution and may comprise approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of
Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 %wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 6.3 wt % of Chrysanthemum indicum, approximately 4.7 wt% of Taraxacum mongolicum, approximately 4.2 wt% of Viola yedoensis, approximately 2.6 wt% of Dolichos lablab, and approximately 6.1wt% of Coix lachryma-jobi.
[57] The composition may further comprise Scaphium scaphigerum, Chrysanthemum indicum, Taraxacum mongolicum, Houttuynia cordata, Gardenia jasminoides in the therapeutically effective combination for a dietary version for a subject having a hot body constitution and may comprise approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, 8.7 wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 6.5 wt% of Scaphium scaphigerum, approximately 6.5 wt % of Chrysanthemum indicum, approximately 5.9 wt% of Taraxacum mongolicum, approximately 4.6 wt% of Houttuynia cordata, and approximately 4.8 wt% of Gardenia jasminoides.
[58] The composition may further comprise Gardenia jasminoides, Nelumbo nucifera, Lophatherum gracile, Houttuynia cordata , Agastache rugosa, Dolichos lablab, Coix lachryma-jobi in the therapeutically effective combination for a dampness resolving dietary version for a subject having a hot body constitution and may comprise approximately 6.8 wt% of Angelica dahurica, approximately 3.2 wt% of Elsholtzia splendens, approximately 6.0 wt% of Lonicera japonica, approximately 9.1 wt% of Glycine max, approximately 7.8 wt% Siraitia grosvenorii, approximately 7.8 wt% of Zingiber officinale, approximately 9.1 wt% of Platycodon grandifloras, approximately 7.8 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.2 wt% of Allium cepa, approximately 7.8 wt% of Glycyrrhiza uralensis, approximately 3.2 wt% of Prunus persica, approximately 9.1 wt% of Gardenia jasminoides, approximately 2.7 wt% of Nelumbo nucifera, approximately 4.6 wt% of Lophatherum gracile, approximately 4.1 wt% of Houttuynia cordata , approximately 1.4 wt % of Agastache rugosa, approximately 2.7 wt% of Dolichos lablab, and approximately 5.0 wt% of Coix lachryma-jobi.
[59] The composition may further comprise Dioscorea oppositifolia, Astragalus membranaceus, Cinnamomum cassia, Zingiber officinale(Dry), Amomum villosum, and Cornus officinalis in the therapeutically effective combination for a medicinal version for a subject having a weak body constitution and may comprise approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, 8.7 wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 4.3 wt% of Dioscorea oppositifolia, approximately 13.0 wt% of Astragalus membranaceus, 1.1 wt% Cinnamomum cassia, 2.2 wt % of Zingiber officinale(Dry), 2.2 wt% of Amomum villosum, and 5.4 wt% Cornus officinalis.
[60] The composition may further comprise Dioscorea oppositifolia, Astragalus membranaceus, Cinnamomum cassia, Zingiber officinale(Dry), Amomum villosum, Cornus officinalis, Dolichos lablab, Coix lachryma-jobi in the therapeutically effective combination for a dampness resolving medicinal version for a subject having a weak body constitution and may comprise approximately 7.0 wt% of Angelica dahurica, approximately 3.3 wt% of Elsholtzia splendens, approximately 6.0 wt% of Lonicera japonica, approximately 9.3 wt% of Glycine max, approximately 7.9 wt% Siraitia grosvenorii, approximately 7.9 wt% of Zingiber officinale, 9.3 wt% of Platycodon grandifloras, approximately 7.9 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.3 wt% of Allium cepa, approximately 7.9 wt% of Glycyrrhiza uralensis, approximately 3.3 wt% of Prunus persica, approximately 4.7 wt% of Dioscorea oppositifolia, approximately 9.3 wt% of Astragalus membranaceus, approximately 1.2 wt% Cinnamomum cassia, approximately 1.2 wt % of Zingiber officinale(Dry), approximately 1.2 wt% of Amomum villosum, approximately 5.8 wt% Cornus officinalis, approximately 2.3 wt% of Dolichos lablab and approximately 4.7 wt% of Coix lachryma-jobi.
[61] The composition may further comprise Dioscorea oppositifolia, Astragalus membranaceus, Cinnamomum cassia, Zingiber officinale(Dry), Amomum villosum, Cornus officinalis, Dolichos lablab, Coix lachryma-jobi in the therapeutically effective combination for a dampness resolving medicinal version for a subject having a weak body constitution that may comprise approximately 7.0 wt% of Angelica dahurica, approximately 3.3 wt% of Elsholtzia splendens, approximately 6.0 wt% of Lonicera japonica, approximately 9.3 wt% of Glycine max, approximately 7.9 wt% Siraitia grosvenorii, approximately 7.9 wt% of Zingiber officinale, 9.3 wt% of Platycodon grandifloras, approximately 7.9 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.3 wt% of Allium cepa, approximately 7.9 wt% of Glycyrrhiza uralensis, approximately 3.3 wt% of Prunus persica, approximately 4.7 wt% of Dioscorea oppositifolia, approximately 9.3 wt% of Astragalus membranaceus, approximately 1.2 wt% Cinnamomum cassia, approximately 1.2 wt % of Zingiber officinale(Dry), approximately 1.2 wt% of Amomum villosum, approximately 5.8 wt% Cornus officinalis, approximately 2.3 wt% of Dolichos lablab and approximately 4.7 wt% of Coix lachryma-jobi.
[62] The composition may further comprise Dioscorea oppositifolia, Astragalus membranaceus, Cinnamomum cassia, Zingiber officinale(Dry), Amomum villosum, Cornus officinalis in the therapeutically effective combination for a dietary version for a subject having a weak body constitution and comprise approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, 8.7 wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 5.4 wt% of Dioscorea oppositifolia, approximately 13 wt% of Astragalus membranaceus, approximately 1.1 wt% of Cinnamomum cassia, approximately 2.2 wt% of Zingiber officinale(Dry), approximately 2.2 wt% of Amomum villosum, and approximately 4.3 wt % of Cornus officinalis.
[63] The composition may further comprise Dioscorea oppositifolia, Euryale ferox, Amomum villosum, Astragalus membranaceus, Agastache rugosa, Dolichos lablab, Coix lachryma-jobi in the therapeutically effective combination for a dampness resolving dietary version for a subject having a weak body constitution and may comprise approximately 6.9 wt% of Angelica dahurica, approximately 3.2 wt% of Elsholtzia splendens, approximately 5.9 wt% of Lonicera japonica, approximately 9.1 wt% of Glycine max, approximately 7.8 wt% Siraitia grosvenorii, approximately 7.8 wt% of Zingiber officinale, 9.1 wt% of Platycodon grandifloras, approximately 7.8 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.2 wt% of Allium cepa, approximately 7.8 wt% of Glycyrrhiza uralensis, approximately 3.2 wt% of Prunus persica, approximately 4.6 wt %of Dioscorea oppositifolia, approximately 4.6 wt% Euryale ferox, approximately 2.3 wt% of Amomum villosum, approximately 9.1 wt% of Astragalus membranaceus, approximately 1.4 wt% of Agastache rugosa, approximately 2.7 wt% of Dolichos lablab, and approximately 5.0 wt% of Coix lachryma jobi.
[64] Other aspects of the invention are also disclosed.
Field of the Invention
[65] The present invention relates to a compound herbal composition for treatment of COVID 19, symptoms of COVID-19 and/or other respiratory conditions.
[66] For example, the present invention also relates to compound herbal composition for prevention and treatment of pneumonia, lung complications, acute respiratory syndrome, persistent pulmonary damage, post-viral fatigue, and chronic cardiac complications resulted from virus infections such as COVID19.
[67] The present invention also relates to a compound herbal composition for the prevention and treatment of symptoms caused by viral infections including fever, headache, cough, chills, muscle aches and pains, fatigue, stomach conditions and difficulty in breathing.
Description of Embodiments
[68] The present invention comprises a foundation formulation comprising:
Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandiflorus, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica.
[69] The invention provides formulations suitable for three types of body constitutions and is optimised for Australian geographic and demographic conditions.
[70] Described below are 12 different variations of the formulation. The 12 different variations are categorized according to four body types.
[71] If there are significant physical and/or psychological stressors, the body can no longer keep its own bodily condition balanced and subsequently enter a state of "sub-health" (sub-optimal health). The compound herbal compositions are specially designed for three different types of unhealthy body constitutions i.e. Heat, Cold, and Weak.
[72] As is known in the art of Chinese compound herbal medications, an "unhealthy" body constitution such as "Heat", "Dampness-heat", "Cold", "Cold-dampness", "Weak", "Weak-dampness", and "Heat- or Cold- dryness" is characterised by subnormal body temperature and other clinical manifestations.
[73] The Dampness resolving variants can sorted into the Qu Shi Pai Du decoction range, and the others under Qing Fei Pai Du decoction range.
[74] Variants for the four body types comprise: medicinal version, dampness resolving medicinal version, dietary version and dampness resolving dietary version.
[75] In an example of a therapeutically effective compound herbal composition, the foundation formulation comprises: Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonica 1.3g, Glycine max 2.0, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g.
[76] Twelve types of formulations with their relative weights are set out below:
[77] Cold Body Constitution
[78] Medicinal version:
[79] The medicinal version of the compound herbal composition comprises Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Scutellaria baicalensis, and Forsythia suspensa in addition to the foundation formulation.
[80] An effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica, Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Scutellaria baicalensis, and Forsythia suspensa in the therapeutically effective combination for a medicinal version for a subject having a cold body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 10 wt% of Platycodon grandifloras, approximately 12 wt % of Imperata cylindrica, approximately 5.0 wt% of Phragmites australis, approximately 4.2 wt% of Allium cepa, approximately 10.3 wt % of Glycyrrhiza uralensis, approximately 4.2 wt% of Prunus persica, approximately 5.9 wt% Tetradium ruticarpum, approximately 4.8 wt% Alpinia oxyphylla, approximately 5.4 wt% Cullen corylifolium, approximately 5.2 wt% Cornus officinalis, approximately 3.6 wt% Scutellaria baicalensis, and approximately 3.5 wt% Forsythia suspensa.
[81] An example of a therapeutically effective compound herbal composition of a medicinal version for a subject having a cold body constitution is as follows:
Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandifloras 2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g, Tetradium ruticarpum 1.35g, Alpinia oxyphylla 1.1g, Cullen corylifolium 1.23g, Cornus officinalis 1.2g, Scutellaria baicalensis 0.82g, Forsythia suspensa 0.8g, maltodextrin.
[82] Dampness resolving medicinal version:
[83] The dampness resolving medicinal version of the compound herbal composition comprises Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Dolichos lablab, and Coix lachryma-jobi in addition to the foundation formulation.
[84] An effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras
, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica, Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Dolichos lablab, and Coix lachryma-jobi in the therapeutically effective combination for a dampness resolving medicinal version for a subject having a cold body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 8.7 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 % of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 5.7 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 5.7 wt% of Tetradium ruticarpum, approximately 4.8 wt% of Alpinia oxyphylla, approximately 5.2 wt% of Cullen corylifolium, approximately 5.2 wt% of Cornus officinalis, approximately 2.6 wt% of Dolichos lablab, and approximately 4.8 wt% Coix lachryma-jobi.
[85] An example of a therapeutically effective compound herbal composition for a dampness resolving medicinal version for a subject having a cold body constitution is as follows:
Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g, Tetradium ruticarpum 1.3g, Alpinia oxyphylla 1.1g, Cullen corylifolium 1.2g, Cornus officinalis 1.2g, Dolichos lablab 0.6g, Coix lachryma-jobi 1.1g, maltodextrin.
[86] Dietary version:
[87] The dietary version of the compound herbal composition comprises Agastache rugosa, Myristica fragrans, Cinnamomum cassia, Zingiber officinale (Dry), and Alpinia oxyphylla.
[88] An effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica, Agastache rugosa, Myristica fragrans, Cinnamomum cassia, Zingiber officinale(Dry), Alpinia oxyphylla in a therapeutically effective combination for a dietary version for a subject having a cold body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 % of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately approximately 5.7 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 1.1 wt% of Agastache rugosa, approximately 7.3 wt% of Myristica fragrans, approximately 1.5 wt% of Cinnamomum cassia, approximately 11.1 wt% of Zingiber officinale(Dry) and approximately 7.3 wt% of Alpinia oxyphylla.
[89] An example of a therapeutically effective compound herbal composition for a dietary version for a subject having a cold body constitution is as follows:
Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g,
Prunus persica 0.7g, Agastache rugosa 0.25g, Myristica fragrans 1.68g, Cinnamomum cassia 0.34g, Zingiber officinale(Dry) 2.55g, Alpinia oxyphylla 1.68g, maltodextrin
[90] Dampness resolving dietary version:
[91] The dampness resolving dietary version of the compound herbal composition comprises Agastache rugosa, Myristica fragrans, Cinnamomum cassia, Zingiber officinale (Dry), and Alpinia oxyphylla in addition to the foundation formulation.
[92] An effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica, Foeniculum vulgare, Zanthoxylum bungeanum, Zingiber officinale(Dry), Astragalus membranaceus, Agastache rugosa, Dolichos lablab, and Coix lachryma-jobi in the therapeutically effective combination for dampness resolving dietary version for a subject having a cold body constitution comprises approximately 6.8 wt% of Angelica dahurica, approximately 3.2 wt% of Elsholtzia splendens, approximately 5.9 wt% of Lonicera japonica, approximately 9.1 wt% of Glycine max, approximately 7.8 wt% Siraitia grosvenorii, approximately 7.8 wt% of Zingiber officinale, approximately 9.1
% of Platycodon grandifloras, approximately 7.8 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.2 wt% of Allium cepa, approximately 7.8 wt% of Glycyrrhiza uralensis, approximately 3.2 wt% of Prunus persica, approximately 4.6 wt% of Foeniculum vulgare, approximately 4.6 wt% of Zanthoxylum bungeanum, approximately 4.6 wt % of Zingiber officinale(Dry), approximately 6.8 wt% of Astragalus membranaceus, approximately 1.4 wt% of Agastache rugosa, approximately 2.8 wt% of Dolichos lablab, and approximately 5.0 wt% of Coix lachryma-jobi.
[93] An example of a therapeutically effective combination for dampness resolving dietary version of a compound herbal composition for a subject having a cold body constitution is as follows:
Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g, Foeniculum vulgare 1.0g, Zanthoxylum bungeanum 1.0g, Zingiber officinale(Dry) 1.0g, Astragalus membranaceus 1.5g, Agastache rugosaO.3g, Dolichos lablab 0.6g, Coix lachryma-jobi 1.1g, maltodextrin
[94] Heat Body Constitution
[95] Medicinal version:
[96] A medicinal version of a compound herbal composition for a subject having a hot body constitution comprises Chrysanthemum indicum, Taraxacum mongolicum, Viola yedoensis, Begonia fimbristipula, Scutellaria baicalensis, Forsythia suspensa in addition to the foundation formulation.
[97] A therapeutically effective combination for a medicinal version of a compound herbal composition for a subject having a hot body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 % wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 6.3 wt
% of Chrysanthemum indicum, approximately 4.7 wt% of Taraxacum mongolicum, approximately 4.2 wt% of Viola yedoensis, approximately 4.3 wt% of Begonia fimbristipula, approximately 4.3 wt% Scutellaria baicalensis, and approximately 4.3 wt% of Forsythia suspensa.
[98] An example of a therapeutically effective combination for a medicinal version of a compound herbal composition for a subject having a hot body constitution is as follows:
[99] Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0g, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g, Chrysanthemum indicum 1.45g, Taraxacum mongolicum 1.08g, Viola yedoensis 0.96g, Begonia fimbristipula 1.0g, Scutellaria baicalensis 1.0g, Forsythia suspensa 1.0g, maltodextrin.
[100] Dampness resolving medicinal version:
[101] A Dampness resolving medicinal version for a subject having a hot body constitution comprises: Chrysanthemum indicum, Taraxacum mongolicum, Viola yedoensis, Begonia fimbristipula, Scutellaria baicalensis, Forsythia suspensa.
[102] A therapeutically effective combination for a dampness resolving medicinal version for a subject having a hot body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 % wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 6.3 wt % of Chrysanthemum indicum, approximately 4.7 wt% of Taraxacum mongolicum, approximately 4.2 wt% of Viola yedoensis, approximately 2.6 wt% of Dolichos lablab, and approximately 6.1wt% of Coix lachryma-jobi.
[103] An example of a therapeutically effective combination for a dampness resolving medicinal version for a subject having a hot body constitution is as follows:
Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g, Chrysanthemum indicum 1.45g, Taraxacum mongolicum 1.08g, Viola yedoensis 0.96g, Begonia fimbristipula 1.0g, Dolichos lablab 0.6g, Coix lachryma-jobi 1.41g, maltodextrin.
[104] Dietary version:
[105] A dietary version for a subject having a hot body constitution comprises Scaphium scaphigerum, Chrysanthemum indicum, Taraxacum mongolicum, Houttuynia cordata, Gardenia jasminoides in addition in addition to the foundation formulation.
[106] A therapeutically effective combination for a dietary version for a subject having a hot body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, 8.7 wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 6.5 wt% of Scaphium scaphigerum, approximately 6.5 wt % of Chrysanthemum indicum, approximately 5.9 wt% of Taraxacum mongolicum, approximately 4.6 wt% of Houttuynia cordata, and approximately 4.8 wt% of Gardenia jasminoides.
[107] An example of a therapeutically effective combination for a dietary version for a subject having a hot body constitution is as follows:
Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g, Scaphium scaphigerum 1.5g,Chrysanthemum indicum 1.5g, Taraxacum mongolicum 1.35g, Houttuynia cordata 1.05g, Gardenia jasminoides 1.1g, maltodextrin.
[108] Dampness resolving dietary version:
[109] A Dampness resolving dietary version comprises Gardenia jasminoides, Nelumbo nucifera, Lophatherum gracile, Houttuynia cordata, Agastache rugosa, Dolichos lablab, Coix lachryma-job in addition to the foundation formulation.
[110] A therapeutically effective combination for a dampness resolving dietary version of a compound herbal composition for a subject having a hot body constitution comprises approximately 6.8 wt% of Angelica dahurica, approximately 3.2 wt% of Elsholtzia splendens, approximately 6.0 wt% of Lonicera japonica, approximately 9.1 wt% of Glycine max, approximately 7.8 wt% Siraitia grosvenorii, approximately 7.8 wt% of Zingiber officinale, approximately 9.1 wt% of Platycodon grandifloras, approximately 7.8 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.2 wt% of Allium cepa, approximately 7.8 wt% of Glycyrrhiza uralensis, approximately 3.2 wt% of Prunus persica, approximately 9.1 wt% of Gardenia jasminoides, approximately 2.7 wt% of Nelumbo nucifera, approximately 4.6 wt% of Lophatherum gracile, approximately 4.1 wt% of Houttuynia cordata , approximately 1.4 wt % of Agastache rugosa, approximately 2.7 wt% of Dolichos lablab, and approximately 5.0 wt% of Coix lachryma-jobi.
[111] An example of a therapeutically effective combination for a dampness resolving dietary version of a compound herbal composition for a subject having a hot body constitution is as follows:
[112] Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g, Gardenia jasminoides 2.0g, Nelumbo nucifera 0.6g, Lophatherum gracile 1.0g, Houttuynia cordata 0.9g, Agastache rugosa 0.3g, Dolichos lablab 0.6g, Coix lachryma-jobi 1.1g, maltodextrin.
[113] Weak Body Constitution
[114] Medicinal version:
[115] A medicinal version of a compound herbal composition for a subject having a weak body constitution comprises Dioscorea oppositifolia, Astragalus membranaceus, Cinnamomum cassia, Zingiber officinale(Dry), Amomum villosum, and Cornus officinalis in addition to the foundation formulation.
[116] A therapeutically effective combination for a medicinal version of a compound herbal composition for a subject having a weak body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, 8.7 wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 4.3 wt% of Dioscorea oppositifolia, approximately 13.0 wt% of Astragalus membranaceus, 1.1 wt% Cinnamomum cassia, 2.2 wt % of Zingiber officinale(Dry), 2.2 wt% of Amomum villosum, and 5.4 wt% Cornus officinalis.
[117] An example of a therapeutically effective combination for a medicinal version of a compound herbal composition for a subject having a weak body constitution is as follows:
Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0g, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g, Dioscorea oppositifolia 1.0g, Astragalus membranaceus 3.0g, Cinnamomum cassia 0.25g, Zingiber officinale(Dry) 0.5g, Amomum villosum 0.5g, Cornus officinalis 1.25g, maltodextrin
[118] Dampness resolving medicinal version:
[119] A dampness resolving medicinal version of a compound herbal composition for a subject having a weak body constitution comprises Dioscorea oppositifolia, Astragalus membranaceus, Cinnamomum cassia, Zingiber officinale(Dry), Amomum villosum, Cornus officinalis, Dolichos lablab, Coix lachryma-jobi in addition to the foundation formulation.
[120] A therapeutically effective combination of a compound herbal composition for a dampness resolving medicinal version for a subject having a weak body constitution comprises approximately 7.0 wt% of Angelica dahurica, approximately 3.3 wt% of Elsholtzia splendens, approximately 6.0 wt% of Lonicera japonica, approximately 9.3 wt% of Glycine max, approximately 7.9 wt% Siraitia grosvenorii, approximately 7.9 wt% of Zingiber officinale, 9.3 wt% of Platycodon grandifloras, approximately 7.9 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.3 wt% of Allium cepa, approximately 7.9 wt% of Glycyrrhiza uralensis, approximately 3.3 wt% of Prunus persica, approximately 4.7 wt% of Dioscorea oppositifolia, approximately 9.3 wt% of Astragalus membranaceus, approximately 1.2 wt% Cinnamomum cassia, approximately 1.2 wt % of Zingiber officinale(Dry), approximately 1.2 wt% of Amomum villosum, approximately 5.8 wt% Cornus officinalis, approximately 2.3 wt% of Dolichos lablab and approximately 4.7 wt% of Coix lachryma-jobi.
[121] An example of a therapeutically effective compound combination for a dampness resolving medicinal version of a compound herbal composition for a subject having a weak body constitution is as follows:
Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0g, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g, Dioscorea oppositifolia 1.0g, Astragalus membranaceus 2.0g, Cinnamomum cassia 0.25g, Zingiber officinale(Dry) 0.25g, Amomum villosum 0.25g, Cornus officinalis 1.25g, Dolichos lablab 0.5g, Coix lachryma-jobi 1.0g, maltodextrin
[122] Dietary version:
[123] A dietary version of a compound herbal composition for a subject having a weak body constitution comprises Dioscorea oppositifolia, Astragalus membranaceus, Cinnamomum cassia, Zingiber officinale(Dry), Amomum villosum, Cornus officinalis, Dolichos lablab, Coix lachryma-jobi in addition to the foundation formulation.
[124] A therapeutically effective combination for a dietary version of a compound herbal composition for a subject having a weak body constitution comprises approximately 7.0 wt% of Angelica dahurica, approximately 3.3 wt% of Elsholtzia splendens, approximately 6.0 wt% of Lonicera japonica, approximately 9.3 wt% of Glycine max, approximately 7.9 wt% Siraitia grosvenorii, approximately 7.9 wt% of Zingiber officinale, 9.3 wt% of Platycodon grandifloras, approximately 7.9 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.3 wt% of Allium cepa, approximately 7.9 wt% of Glycyrrhiza uralensis, approximately 3.3 wt% of Prunus persica, approximately 4.7 wt% of Dioscorea oppositifolia, approximately 9.3 wt% of Astragalus membranaceus, approximately 1.2 wt% Cinnamomum cassia, approximately 1.2 wt % of Zingiber officinale(Dry), approximately 1.2 wt% of Amomum villosum, approximately 5.8 wt% Cornus officinalis, approximately 2.3 wt% of Dolichos lablab and approximately 4.7 wt% of Coix lachryma-jobi.
[125] An example of a dietary version of a compound herbal composition for a subject having a weak body constitution is as follows:
Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0g, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g, Dioscorea oppositifolia 1.25g, Astragalus membranaceus 3.0g, Cinnamomum cassia 0.25g, Zingiber officinale (Dry) 0.5g, Amomum villosum 0.5g, Cornus officinalis 1.0g, maltodextrin.
[126] Dampness resolving dietary version:
[127] A dampness resolving dietary version for a subject having a weak body constitution further comprises Dioscorea oppositifolia, Euryale ferox, Amomum villosum, Astragalus membranaceus, Agastache rugosa, Dolichos lablab, Coix lachryma-jobi.
[128] A therapeutically effective combination for a dampness resolving dietary version of a compound herbal composition for a subject having a weak body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, 8.7 wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 5.4 wt% of Dioscorea oppositifolia, approximately 13 wt% of Astragalus membranaceus, approximately 1.1 wt% of Cinnamomum cassia, approximately 2.2 wt% of Zingiber officinale(Dry), approximately 2.2 wt% of Amomum villosum, and approximately 4.3 wt % of Cornus officinalis.
[129] An example of a dampness resolving dietary version of the compound herbal composition for a subject having a weak body constitution is as follows:
Angelica dahurica 1.5g, Elsholtzia splendens 0.7g, Lonicera japonican 1.3g, Glycine max 2.0, Siraitia grosvenorii 1.7g, Zingiber officinale 1.7g, Platycodon grandiflorus2.0g, Imperata cylindrica 1.7g, Phragmites australis 0.8g, Allium cepa 0.7g, Glycyrrhiza uralensis 1.7g, Prunus persica 0.7g, Dioscorea oppositifolia 1.0g,Euryale ferox 1.0g, Amomum villosum 0.5g, Astragalus membranaceus 2.0g, Agastache rugosa 0.3g, Dolichos lablab 0.6g, Coix lachryma-jobi 1.1g, maltodextrin.
[130] The example compositions can include suitable additives. The 12 examples provided above include maltodextrin as an additive but it is envisaged that in other embodiments, other additives can be used.
[131] The compound herbal composition can be provided in any one of the following dosage forms: powdered form or tablet or capsule or paste or liquid form for oral consumption, or inhalants or injectable liquid.
[132] In some examples, the liquid form for oral consumption can be a concentrated or a diluted drink including water or other suitable dilutant.
[133] It can also be taken four times a day when the symptoms are in severe symptoms, take it every 3-4 hours.
In a hospital COVID patients were treated only with herbal compositions of the present invention. Out of 564 patients, 482 patients were recovered in 26 days, with a success rate of 85.5%. Patients under treatment did not suffer reinfection and their conditions were stabilised without other medical interventions, with fewer cases of persistent pulmonary damage and acute respiratory syndrome. On average, patient recovery time was shortened, with lower symptom deterioration rate, less cases of viral induced pneumonia and other pulmonary complications. No medical staff were suffered from COVID infections.
[134] Examples of the use of medicinal versions of the compositions for each of the Heat, Cold and Wet body constitutions are as follows.
[135] Example of using the composition for treatment of a patient with a Heat body constitution with dampness
2:3
[136] Symptoms of patient: Cough, yellow phlegm, sore throat, headache, mild fever, muscle pain, dry mouth, constipation and tiredness and sleepy for two days. Red tongue, Thick and greasy tongue coating, Floating and rapid and slippery pulse.
[137] Example Composition 1
Component Amount (for two doses)
Radix angelicae dahuricae 1.5g
Herba moslae 0.7g
Flos lonicerae japonicae 1.3g
Semen sojae preparatum 2.Og
Fructus momordicae 1.7g
Rhizoma zingiberis recens 1.7g
Radix platycodonis 2.Og
Rhizoma phragmitis 1.7g
Rhizoma imperatae 0.8g
Fistular onion stalk 0.7g
Radix et rhizome glycyrhizae 1.7g
Semen persicae 0.7g
Flos chrysanthemi indici 1.45g
Herba taraxaci 1.08g
Herba violae 0.96g
Muskroot-like Semiaquilegia Root 1.0g
Flower of Hyacinth Bean 0.6g
Semen cuicis 1.41g
[138] Dosage regimen: The patient took a single dose of granules of the composition twice a day. Each dose was taken approximately 30 minutes after a meal with boiled water.
[139] Results: After 2-3 days, the symptoms relieved. After 6-7 days, other symptoms disappeared except tiredness. The symptoms of tiredness disappeared in two weeks.
[140] Example of using the composition for treatment of a patient with a Cold body constitution with dampness
[141] Symptoms of patient: Cough, white phlegm, sore throat, dripping nose, headache, muscle pain, limbs cold, diarrhea, and tiredness sleepy for two days. White tongue, Thick and greasy tongue coating, Floating and slippery pulse.
[142] Example Composition 2
[143]
Amount (for two Component doses)
Radix angelicae dahuricae 1.5g
Herba moslae 0.7g
Flos lonicerae japonicae 1.3g
Semen sojae preparatum 2.Og
Fructus momordicae 1.7g
Rhizoma zingiberis recens 1.7g
Radix platycodonis 2.Og
Rhizoma phragmitis 1.7g
Rhizoma imperatae 0.8g
Fistular onion stalk 0.7g
Radix et rhizome glycyrhizae 1.7g
Fructus evodiae 1.35g
Fructus alpiniae oxyphyllae 1.1g
Fructus psoraleae 1.23g
Fructus corni 1.2g
Flower of Hyacinth Bean 0.6g
Semen cuicis 1.1g
[144] Dosage regimen: The patient took a single dose of granules of the composition twice a day. Each dose was taken approximately 30 minutes after a meal with boiled water.
[145] Results: After 2-3 days, the symptoms relieved. After 6-7 days, other symptoms disappeared except tiredness. The symptoms of tiredness disappeared in two weeks.
[146] Example of using the composition for treatment of a patient with a Weak body constitution with dampness
[147] Symptoms of patient:
[148] Cough with phlegm, sore throat, headache, spontaneous sweating muscle pain, poor appetite and weakness and sleepy for two days. Pale tongue, Thick and greasy tongue coating, Soft and slippery pulse.
[149] Example Composition 3
Component Amount (for two doses)
Radix angelicae dahuricae 1.5g
Herba moslae 0.7g
Flos lonicerae japonicae 1.3g
Semen sojae preparatum 2.Og
Fructus momordicae 1.7g
Rhizoma zingiberis recens 1.7g
Radix platycodonis 2.Og
Rhizoma phragmitis 1.7g
Rhizoma imperatae 0.8g
Fistular onion stalk 0.7g
Radix et rhizome glycyrhizae 1.7g
Semen persicae 0.7g
Rhizoma dioscoreae 1.0g
Radix Astragali 2.Og
Cortex Cinnamomi 0.25g
Rhizoma Zingiberis 0.25g
Fructus amomi 0.25g
Fructus Corni 1.25g
Flower of Hyacinth Bean 0.5g
Semen cuicis 1.0g
[150] Dosage regimen: The patient took a single dose of granules of the composition twice a day. Each dose was taken approximately 30 minutes after a meal with boiled water.
[151] Results: After 2-3 days, the symptoms relieved. After 6-7 days, other symptoms disappeared except tiredness. The symptoms of tiredness disappeared in two weeks.
[152] Example of using the composition for treatment of a patient with a Heat body constitution without dampness
[153] Symptoms of patient: Cough, sore throat, headache, mild fever, muscle pain, dry mouth, constipation anxiety and tiredness for two days. Red tongue, Floating and rapid and pulse.
[154] Example Composition 4
Component Amount (for two doses)
Radix angelicae dahuricae 1.5g
Herba moslae 0.7g
Flos lonicerae japonicae 1.3g
Semen sojae preparatum 2.Og
Fructus momordicae 1.7g
Rhizoma zingiberis recens 1.7g
Radix platycodonis 2.Og
Rhizoma phragmitis 1.7g
Rhizoma imperatae 0.8g
Fistular onion stalk 0.7g
Radix et rhizome glycyrhizae 1.7g
Semen persicae 0.7g
Flos chrysanthemi indici 1.45g
Herba taraxaci 1.08g
Herba violae 0.96g
Muskroot-like Semiaquilegia Root 1.0g
Radix scutellariae 1.0g
Fructus forsythia 1.01g
[155] Dosage regimen: The patient took a single dose of granules of the composition twice a day. Each dose was taken approximately 30 minutes after a meal with boiled water.
[156] Results: After 2-3 days, the symptoms relieved. After 6-7 days, other symptoms disappeared except tiredness. The symptoms of tiredness disappeared in two weeks.
[157] Example of using the composition for treatment of a patient with a Cold body constitution without dampness
[158] Symptoms of patient:
[159] Cough, sore throat, dripping nose, headache, muscle pain, limbs cold, diarrhea, and tiredness for two days. White tongue, Thin white tongue coating, Floating tight pulse.
[160] Example Composition 5
Amount (for two Component doses)
Herba moslae 0.7g
Flos lonicerae japonicae 1.3g
Semen sojae preparatum 2.Og
Fructus momordicae 1.7g
Rhizoma zingiberis recens 1.7g
Radix platycodonis 2.Og
Rhizoma phragmitis 1.7g
Rhizoma imperatae 0.8g
Fistular onion stalk 0.7g
Radix et rhizome glycyrhizae 1.7g
Semen persicae 0.7g
Fructus Evodiae 1.35g
Fructus alpiniae oxyphyllae 1.1g
Fructus Psoraleae 1.23g
Fructus Corni 1.2g
Radix scutellariae 0.82g
Fructus Forsythiae 0.8g
[161] Dosage regimen: The patient took a single dose of granules of the composition twice a day. Each dose was taken approximately 30 minutes after a meal with boiled water.
[162] Results: After 2-3 days, the symptoms relieved. After 6-7 days, other symptoms disappeared except tiredness. The symptoms of tiredness disappeared in two weeks.
[163] Example of using the composition for treatment of a patient with a Weak body constitution without dampness
[164] Symptoms of patient:
[165] Cough, sore throat, headache, spontaneous sweating, muscle pain, poor appetite and weakness for two days. Light-whitish tongue coating, Floating and weak pulse.
[166] Example Composition 6
Amount (for two Component doses)
Herba moslae 0.7g
Flos lonicerae japonicae 1.3g
Semen sojae preparatum 2.Og
Fructus momordicae 1.7g
Rhizoma zingiberis recens 1.7g
Radix platycodonis 2.Og
Rhizoma phragmitis 1.7g
Rhizoma imperatae 0.8g
Fistular onion stalk 0.7g
Radix et rhizome glycyrhizae 1.7g
Semen persicae 0.7g
Fructus Evodiae 1.35g
Fructus alpiniae oxyphyllae 1.1g
Fructus Psoraleae 1.23g
Fructus Corni 1.2g
Radix scutellariae 0.82g
Fructus Forsythiae 0.8g
[167] Dosage regimen: The patient took a single dose of granules of the composition twice a day. Each dose was taken approximately 30 minutes after a meal with boiled water.
[168] Results: After 2-3 days, the symptoms relieved. After 6-7 days, other symptoms disappeared except tiredness. The symptoms of tiredness disappeared in two weeks.
[169] Herbal formulations are provided which reduce the occurrence of viral infections and can prevent and treat complications associated with COVID-19.
[170] The invention provides compositions for use in treating COVID-19 or other viral infections, and/or one or more medical conditions resulting from COVID-19 in a subject in need thereof.
[171] The one or more medical conditions can comprise pneumonia and/or acute respiratory syndrome and/or persistent pulmonary damage and/or post-viral fatigue and/or chronic cardiac complications.
[172] The compound herbal compositions can prevent occurrence and/or reduce severity of one or more medical conditions resulting from COVID-19 and/or improve human body immunity.
[173] The compositions have been found to be effective in treating a range of symptoms including cough, fever, fatigue, difficulty in breathing, dry throat, bitterness in the mouth, and symptoms of mental exhaustion.
[174] These formulations can substantially reduce the possibility of organ deterioration and greatly increase survival rate.
Interpretation
Embodiments:
[175] Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to one of ordinary skill in the art from this disclosure, in one or more embodiments.
[176] Similarly, it should be appreciated that in the above description of example embodiments of the invention, various features of the invention are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure and aiding in the understanding of one or more of the various inventive aspects. This method of disclosure, however, is not to be interpreted as reflecting an intention that the claimed invention requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment. Thus, the claims following the Detailed Description of Specific Embodiments are hereby expressly incorporated into this Detailed Description of Specific Embodiments, with each claim standing on its own as a separate embodiment of this invention.
[177] Furthermore, while some embodiments described herein include some but not other features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention, and form different embodiments, as would be understood by those in the art. For example, in the following claims, any of the claimed embodiments can be used in any combination.
Different Instances of Objects
[178] As used herein, unless otherwise specified the use of the ordinal adjectives "first", "second", "third", etc., to describe a common object, merely indicate that different instances of like objects are being referred to, and are not intended to imply that the objects so described must be in a given sequence, either temporally, spatially, in ranking, or in any other manner.
:32
Specific Details
[179] In the description provided herein, numerous specific details are set forth. However, it is understood that embodiments of the invention may be practiced without these specific details. In other instances, well-known methods, structures and techniques have not been shown in detail in order not to obscure an understanding of this description.
Comprising and Including
[180] In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" are used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
[181] Any one of the terms: including or which includes or that includes as used herein is also an open term that also means including at least the elements/features that follow the term, but not excluding others. Thus, including is synonymous with and means comprising.
Scope of Invention
[182] Thus, while there has been described what are believed to be the preferred embodiments of the invention, those skilled in the art will recognize that other and further modifications may be made thereto without departing from the spirit of the invention, and it is intended to claim all such changes and modifications as fall within the scope of the invention. For example, any formulas given above are merely representative of procedures that may be used. Functionality may be added or deleted from the block diagrams and operations may be interchanged among functional blocks. Steps may be added or deleted to methods described within the scope of the present invention.
[183] Although the invention has been described with reference to specific examples, it will be appreciated by those skilled in the art that the invention may be embodied in many other forms.
:3:3
Industrial Applicability
[184] It is apparent from the above, that the arrangements described are applicable to the alternative or herbal medication industries.
Claims (5)
1. A compound herbal composition when used for treatment of or prevention of COVID 19 and/or treatment of or prevention of one or more of medical conditions resulting from COVID-19, comprising: Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Playcodon grandifloras , Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica, wherein the composition is prepared by compounding a therapeutically effective combination of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras
, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica.
2. The composition of claim 1, wherein an effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras , Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica in the therapeutically effective combination comprises between 6.5 wt% to 10wt% of Angelica dahurica, between 3 to 4.5 wt% of Elsholtzia splendens, between 5.5 wt% to 8 wt% of Lonicera japonica, between 8.5 wt% to 12.5wt% of Glycine max, between 7 wt% to 10.5wt% of Siraitia grosvenorii, between 7 wt% to 10.5 wt% of Zingiber officinale, between 8.5 wt% to 12.5% of Platycodon grandifloras, between 7.5 wt% to 10.5 wt % of Imperata cylindrica, between 3.0 wt% to 5.0 wt% of Phragmites australis, between 3.0 wt% to 4.5 wt% of Allium cepa, between 7 wt% to 10.5 wt% of Glycyrrhiza uralensis and between 3 wt% to 4.5 wt% of Prunus persica.
3. Use of the compound herbal composition of claim 1 or 2 in a therapeutically effective amount in the manufacture of a medicament for administration to a patient in the therapeutic treatment of and/or prevention of COVID-19 and/or treatment of and/or prevention of one or more of medical conditions resulting from COVID-19.
4. A method of treating COVID-19 and/or one or more medical conditions resulting from COVID-19 in a subject in need thereof, comprising administering a therapeutically effective amount of the compound herbal composition according to any one of claims 1 or 2.
5. The composition of claim 1 or claim 2, further comprising Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras , Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica, wherein an effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras
, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica in the therapeutically effective combination for a medicinal version for a cold body constitution comprises approximately 9 wt% of Angelica dahurica, approximately 4 wt% of Elsholtzia splendens, approximately 7.8 wt% of Lonicera japonica, approximately 12.5wt% of Glycine max, approximately 10 wt% Siraitia grosvenorii, approximately 10 wt% of Zingiber officinale, 10 % of Platycodon grandifloras, approximately 12 wt % of Imperata cylindrica, 5.0 wt% of Phragmites australis, 4.2 wt% of Allium cepa, approximately 10.3 wt% of Glycyrrhiza uralensis and 4.2 wt% of Prunus persica, or further comprising Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Scutellaria baicalensis, and Forsythia suspensa, wherein an effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras , Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica, Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Scutellaria baicalensis, and Forsythia suspensa in the therapeutically effective combination for a medicinal version for a subject having a cold body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 10 wt% of Platycodon grandifloras, approximately 12 wt % of Imperata cylindrica, approximately 5.0 wt% of Phragmites australis, approximately 4.2 wt% of Allium cepa, approximately 10.3 wt % of Glycyrrhiza uralensis, approximately 4.2 wt% of Prunus persica, approximately 5.9 wt% Tetradium ruticarpum, approximately 4.8 wt% Alpinia oxyphylla, approximately 5.4 wt% Cullen corylifolium, approximately 5.2 wt% Cornus officinalis, approximately 3.6 wt% Scutellaria baicalensis, and approximately 3.5 wt% Forsythia suspensa, or further comprising Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Dolichos lablab, and Coix lachryma-jobi, wherein an effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras , Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica, Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Dolichos lablab, and Coix lachryma-jobi in the therapeutically effective combination for a dampness resolving medicinal version for a subject having a cold body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 8.7 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 % of Platycodon grandifloras, approximately 7.4 wt
% of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 5.7 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 5.7 wt% of Tetradium ruticarpum, approximately 4.8 wt% of Alpinia oxyphylla, approximately 5.2 wt% of Cullen corylifolium, approximately 5.2 wt% of Cornus officinalis, approximately 2.6 wt% of Dolichos lablab, and approximately 4.8 wt% Coix lachryma-jobi, or further comprising Agastache rugosa, Myristica fragrans, Cinnamomum cassia, Zingiber officinale (Dry), and Alpinia oxyphylla, wherein an effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras , Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica, Agastache rugosa, Myristica fragrans, Cinnamomum cassia, Zingiber officinale(Dry), Alpinia oxyphylla in the therapeutically effective combination for a dietary version for a subject having a cold body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 % of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately approximately 5.7 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 1.1 wt% of Agastache rugosa, approximately 7.3 wt% of Myristica fragrans, approximately 1.5 wt% of Cinnamomum cassia, approximately 11.1 wt% of Zingiber officinale(Dry) and approximately 7.3 wt% of Alpinia oxyphylla,or further comprising Foeniculum vulgare, Zanthoxylum bungeanum Astragalus membranaceus, Dolichos lablab and Coix lachryma-jobi wherein an effective amount of each of Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras , Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, Prunus persica, Foeniculum vulgare, Zanthoxylum bungeanum, Zingiber officinale(Dry), Astragalus membranaceus, Agastache rugosa, Dolichos lablab, and Coix lachryma-jobi in the therapeutically effective combination for dampness resolving dietary version for a subject having a cold body constitution comprises approximately 6.8 wt% of Angelica dahurica, approximately 3.2 wt% of Elsholtzia splendens, approximately 5.9 wt% of Lonicera japonica, approximately 9.1 wt% of Glycine max, approximately 7.8 wt% Siraitia grosvenorii, approximately 7.8 wt% of Zingiber officinale, approximately 9.1 % of Platycodon grandifloras, approximately 7.8 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.2 wt% of Allium cepa, approximately 7.8 wt% of Glycyrrhiza uralensis, approximately 3.2 wt% of Prunus persica, approximately 4.6 wt% of Foeniculum vulgare, approximately 4.6 wt% of Zanthoxylum bungeanum, approximately 4.6 wt % of Zingiber officinale(Dry), approximately 6.8 wt% of Astragalus membranaceus, approximately 1.4 wt% of Agastache rugosa, approximately 2.8 wt% of Dolichos lablab, and approximately 5.0 wt% of Coix lachryma-jobi, or further comprising Chrysanthemum indicum, Taraxacum mongolicum, Viola yedoensis, Begonia fimbristipula, Scutellaria baicalensis, Forsythia suspensa in the therapeutically effective combination for a medicinal version for a subject having a hot body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 % wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 6.3 wt % of Chrysanthemum indicum, approximately 4.7 wt% of Taraxacum mongolicum, approximately 4.2 wt% of Viola yedoensis, approximately 4.3 wt% of Begonia fimbristipula, approximately 4.3 wt% Scutellaria baicalensis, and approximately 4.3 wt% of Forsythia suspensa, or further comprising Chrysanthemum indicum, Taraxacum mongolicum, Viola yedoensis, Begonia fimbristipula, Dolichos lablab, Coix Lachryma-jobi in the therapeutically effective combination for a dampness resolving medicinal version for a subject having a hot body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, approximately 8.7 % wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 6.3 wt % of Chrysanthemum indicum, approximately 4.7 wt% of Taraxacum mongolicum, approximately 4.2 wt% of Viola yedoensis, approximately 4.3% of Begonia fimbristipula, approximately 2.6 wt% of Dolichos lablab, and approximately 6.1wt% of Coix lachryma-jobi, or. further comprising Scaphium scaphigerum, Chrysanthemum indicum, Taraxacum mongolicum, Houttuynia cordata, Gardenia jasminoides in the therapeutically effective combination for a dietary version for a subject having a hot body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, 8.7 wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 6.5 wt% of Scaphium scaphigerum, approximately 6.5 wt % of Chrysanthemum indicum, approximately 5.9 wt% of Taraxacum mongolicum, approximately 4.6 wt% of Houttuynia cordata, and approximately 4.8 wt% of Gardenia jasminoides, or further comprising Gardenia jasminoides, Nelumbo nucifera, Lophatherum gracile, Houttuynia cordata , Agastache rugosa, Dolichos lablab, Coix lachryma jobi in the therapeutically effective combination for a dampness resolving dietary version for a subject having a hot body constitution comprises approximately 6.8 wt% of Angelica dahurica, approximately 3.2 wt% of Elsholtzia splendens, approximately 6.0 wt% of Lonicera japonica, approximately 9.1 wt% of Glycine max, approximately 7.8 wt% Siraitia grosvenorii, approximately 7.8 wt% of Zingiber officinale, approximately 9.1 wt% of Platycodon grandifloras, approximately 7.8 wt
% of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.2 wt% of Allium cepa, approximately 7.8 wt% of Glycyrrhiza uralensis, approximately 3.2 wt% of Prunus persica, approximately 9.1 wt% of Gardenia jasminoides, approximately 2.7 wt% of Nelumbo nucifera, approximately 4.6 wt% of Lophatherum gracile, approximately 4.1 wt% of Houttuynia cordata
, approximately 1.4 wt % of Agastache rugosa, approximately 2.7 wt% of Dolichos lablab, and approximately 5.0 wt% of Coix lachryma-jobi, or further comprising Dioscorea oppositifolia, Astragalus membranaceus, Cinnamomum cassia, Zingiber officinale(Dry), Amomum villosum, and Cornus officinalis in the therapeutically effective combination for a medicinal version for a subject having a weak body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, 8.7 wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 4.3 wt% of Dioscorea oppositifolia, approximately 13.0 wt% of Astragalus membranaceus, 1.1 wt% Cinnamomum cassia, 2.2 wt % of Zingiber officinale(Dry), 2.2 wt% of Amomum villosum, and 5.4 wt% Cornus officinalis, or further comprising Dioscorea oppositifolia, Astragalus membranaceus, Cinnamomum cassia, Zingiber officinale(Dry), Amomum villosum, Cornus officinalis, Dolichos lablab, Coix lachryma-jobi in the therapeutically effective combination for a dampness resolving medicinal version for a subject having a weak body constitution comprises approximately 7.0 wt% of Angelica dahurica, approximately 3.3 wt% of Elsholtzia splendens, approximately 6.0 wt% of Lonicera japonica, approximately 9.3 wt% of Glycine max, approximately 7.9 wt% Siraitia grosvenorii, approximately 7.9 wt% of Zingiber officinale, 9.3 wt% of Platycodon grandifloras, approximately 7.9 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.3 wt% of Allium cepa, approximately 7.9 wt% of Glycyrrhiza uralensis, approximately 3.3 wt% of Prunus persica, approximately 4.7 wt% of Dioscorea oppositifolia, approximately 9.3 wt% of Astragalus membranaceus, approximately 1.2 wt% Cinnamomum cassia, approximately 1.2 wt % of Zingiber officinale(Dry), approximately 1.2 wt% of Amomum villosum, approximately 5.8 wt% Cornus officinalis, approximately 2.3 wt% of Dolichos lablab and approximately 4.7 wt% of Coix lachryma-jobi, or further comprising Dioscorea oppositifolia, Astragalus membranaceus, Cinnamomum cassia, Zingiber officinale(Dry), Amomum villosum, Cornus officinalis in the therapeutically effective combination for a dietary version for a subject having a weak body constitution comprises approximately 6.5 wt% of Angelica dahurica, approximately 3.0 wt% of Elsholtzia splendens, approximately 5.7 wt% of Lonicera japonica, approximately 8.7 wt% of Glycine max, approximately 7.4 wt% Siraitia grosvenorii, approximately 7.4 wt% of Zingiber officinale, 8.7 wt% of Platycodon grandifloras, approximately 7.4 wt % of Imperata cylindrica, approximately 3.5 wt% of Phragmites australis, approximately 3.0 wt% of Allium cepa, approximately 7.4 wt% of Glycyrrhiza uralensis, approximately 3.0 wt% of Prunus persica, approximately 5.4 wt% of Dioscorea oppositifolia, approximately 13 wt% of Astragalus membranaceus, approximately 1.1 wt% of Cinnamomum cassia, approximately 2.2 wt% of Zingiber officinale(Dry), approximately 2.2 wt% of Amomum villosum, and approximately 4.3 wt % of Cornus officinalis, or further comprising Dioscorea oppositifolia, Euryale ferox, Amomum villosum, Astragalus membranaceus, Agastache rugosa, Dolichos lablab, Coix lachryma jobi in the therapeutically effective combination for a dampness resolving dietary version for a subject having a weak body constitution comprises approximately 6.9 wt% of Angelica dahurica, approximately 3.2 wt% of Elsholtzia splendens, approximately 5.9 wt% of Lonicera japonica, approximately 9.1 wt% of Glycine max, approximately 7.8 wt% Siraitia grosvenorii, approximately 7.8 wt% of Zingiber officinale, 9.1 wt% of Platycodon grandifloras, approximately 7.8 wt % of Imperata cylindrica, approximately 3.7 wt% of Phragmites australis, approximately 3.2 wt% of Allium cepa, approximately 7.8 wt% of Glycyrrhiza uralensis, approximately 3.2 wt% of Prunus persica, approximately 4.6 wt % of Dioscorea oppositifolia, approximately 4.6 wt% Euryale ferox, approximately 2.3 wt% of Amomum villosum, approximately 9.1 wt% of Astragalus membranaceus, approximately 1.4 wt% of Agastache rugosa, approximately 2.7 wt% of Dolichos lablab, and approximately 5.0 wt% of Coix lachryma-jobi.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021106785A AU2021106785C4 (en) | 2021-08-24 | 2021-08-24 | Combined plant compounds for use in the treatment of viral infections including covid-19 |
AU2022221464A AU2022221464A1 (en) | 2021-08-24 | 2022-08-23 | Combined plant compounds for use in the treatment of viral infections including COVID-19 |
PCT/AU2022/050948 WO2023023721A1 (en) | 2021-08-24 | 2022-08-23 | Combined plant compounds for use in the treatment of viral infections including covid-19 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021106785A AU2021106785C4 (en) | 2021-08-24 | 2021-08-24 | Combined plant compounds for use in the treatment of viral infections including covid-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2021106785A4 AU2021106785A4 (en) | 2021-11-18 |
AU2021106785B4 AU2021106785B4 (en) | 2022-07-07 |
AU2021106785C4 true AU2021106785C4 (en) | 2023-09-21 |
Family
ID=78514128
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021106785A Active AU2021106785C4 (en) | 2021-08-24 | 2021-08-24 | Combined plant compounds for use in the treatment of viral infections including covid-19 |
AU2022221464A Pending AU2022221464A1 (en) | 2021-08-24 | 2022-08-23 | Combined plant compounds for use in the treatment of viral infections including COVID-19 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2022221464A Pending AU2022221464A1 (en) | 2021-08-24 | 2022-08-23 | Combined plant compounds for use in the treatment of viral infections including COVID-19 |
Country Status (2)
Country | Link |
---|---|
AU (2) | AU2021106785C4 (en) |
WO (1) | WO2023023721A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11813287B1 (en) | 2023-03-10 | 2023-11-14 | King Faisal University | Covid-19 binding aerosols |
-
2021
- 2021-08-24 AU AU2021106785A patent/AU2021106785C4/en active Active
-
2022
- 2022-08-23 AU AU2022221464A patent/AU2022221464A1/en active Pending
- 2022-08-23 WO PCT/AU2022/050948 patent/WO2023023721A1/en unknown
Non-Patent Citations (1)
Title |
---|
Luo, H., et al., "Reflections on treatment of COVID-19 with traditional Chinese medicine." Chin Med (2020) 15:94. https://doi.org/10.1186/s13020-020-00375-1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023023721A1 (en) | 2023-03-02 |
AU2021106785A4 (en) | 2021-11-18 |
AU2021106785B4 (en) | 2022-07-07 |
AU2022221464A1 (en) | 2023-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102727686B (en) | Traditional Chinese medicine composition for treating fatty liver | |
CN103705603B (en) | Traditional Chinese medicine for treating acne | |
CN104042802A (en) | Traditional Chinese medicine composition capable of treating fatty liver | |
WO2021179505A1 (en) | Forsythia suspensa and astragalus membranaceus compound preparation, preparation method therefor and application thereof | |
CN104013926A (en) | Traditional Chinese medicine composition and application of traditional Chinese medicine composition as medicine for treating fatty liver | |
CN103432545B (en) | A kind of medicine for pediatrics febricide and preparation method thereof | |
AU2021106785C4 (en) | Combined plant compounds for use in the treatment of viral infections including covid-19 | |
CN105381153A (en) | Traditional Chinese medicine preparation for treating bronchitis and preparation method thereof | |
CN103494968B (en) | Traditional Chinese medicine preparation for treating epidemic parotitis and preparation method thereof | |
CN107260856B (en) | A Chinese medicinal composition for treating hepatitis B, and its preparation method | |
CN111184854A (en) | Chinese medicinal prescription for preventing virus infection | |
CN111407808B (en) | Traditional Chinese medicine composition and preparation method and pharmaceutical application thereof | |
CN111544466B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for preventing neocoronary pneumonia | |
CN114796434A (en) | Pill for keeping healthy qi and pathogenic factors dry | |
CN106474422A (en) | A kind of medicine treating hepatitis B | |
CN105456617A (en) | Oral-administrated traditional Chinese medicine pills for treating symptom of pathogenic fire derived from stagnation of liver and preparation method thereof | |
CN105012500A (en) | Decoction medicament for treating acute mastitis and preparation method thereof | |
CN105106842A (en) | Medicine for treating chronic hepatitis B | |
CN105250772A (en) | Traditional Chinese medicine composition for treating urticaria | |
CN104127631A (en) | Traditional Chinese medicinal composition for treating tinea cruris and tinea inguinalis | |
CN104474514A (en) | Chinese patent medicine for treating children fever | |
CN109331164A (en) | A kind of Chinese medicine composition for treating rabies, Chinese medical extract and preparation method thereof and dosage form | |
CN104096202A (en) | Medicine for treating autumn diarrhea and preparation method of medicine | |
CN104645079A (en) | Traditional Chinese medicine for treating post-stroke limb numbness | |
CN117159679A (en) | Traditional Chinese medicine composition for treating influenza and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGI | Letters patent sealed or granted (innovation patent) | ||
FF | Certified innovation patent | ||
DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 APR 2023 |
|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 APR 2023 |